Hofseth Biocare ASA: HBC Annual Report 2016 approved and completes sale and long-term leaseback contracts
March 31 2017 - 10:47AM
Today, 31 March 2017, the
Board of Directors approved the Annual Report for 2016. There are
no significant changes compared to the fourth quarter report issued
15 February 2017.
Please find the Annual
Report for 2016 attached. Also, the Hofseth BioCare CSR report can
be downloaded from the HBC website
http://www.hofsethbiocare.com/investors/csr/
Hofseth BioCare ASA have at
the same time completed the sale and leaseback transaction with
Syvde Eiendom AS. The plant buildings at Midsund and Berkåk are
sold for a total of NOK 80 million. The sale of the properties will
provide HBC with additional working capital to be used in the
ongoing commercialization of the Company's products, while the
15-year lease agreements secures the Company long-term access to
well-suited factory premises.
For further information,
please contact:
Tor Erik Andersen, CEO of
Hofseth BioCare ASA
Mob: +47 911 79 854
E-mail: tea@hofsethbiocare.no
Jon Olav Ødegård, CFO of
Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
About Hofseth BioCare
ASA:
HBC is a Norwegian biotech company that offers high-value
ingredients and finished products for humans and pets. The company
is founded on the core values of sustainability, traceability and
optimal utilization of natural resources. Through an innovative
hydrolysis technology, HBC can preserve the quality of salmon oil,
proteins and calcium, prepared of fresh salmon off-cuts. HBC's
objective is to contribute to the efficient use of marine resources
and deliver quality products for ingredients and finished consumer
products in the nutrition market.
Hofseth BioCare's
headquarters are in Ålesund, Norway with branches in Oslo, Chicago,
Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list
with ticker "HBC". More information about Hofseth BioCare at
www.hofsethbiocare.com and
www.facebook.com/hofsethbiocare
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.
HBC Arsrapport 2016
HBC Annual Report 2016
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Hofseth Biocare ASA via Globenewswire